共 50 条
- [1] Efficacy of gefitinib combined with bevacizumab versus gefitinib in advanced EGFR L858R NSCLC.[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Zhao, XinminWu, XianghuaWang, HuijieYu, HuiSun, SiFeng, YuWang, Jialei
- [2] Neoantigen screening identifies EGFR L858R mutation immunogenicity in 1862 Chinese NSCLC patients.[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Lin, JinChen, YuChen, GangJun, LiuHao, ShiguangXiong, Jia-niLan, BinXu, YapingGuan, Yan-FangGuo, ZengqingChen, LinChen, Li-zhuXia, Xuefeng
- [3] Concomitant Mutations in EGFR 19Del/L858R Mutation and Their Association with Response to EGFR-TKIs in NSCLC Patients[J]. CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 8653 - 8662Liang, HengruiLi, CaichenZhao, YiZhao, ShenHuang, JunCai, XiuyuCheng, BoXiong, ShanLi, JianfuWang, WeiZhu, ChangbinLi, WeiweiHe, JianxingLiang, Wenhua
- [4] IN-119873, the next-generation allosteric EGFR TKI, a potent and highly selective EGFR L858R for the treatment of osimertinib- resistant NSCLC[J]. CANCER RESEARCH, 2024, 84 (06)Choi, Jong RyoulYoon, DaseulKim, Seo HyunKim, Do GyeongKang, Seock YongChoi, Seong-IlPark, SomyiLee, Hyun KyungKim, DonghyunLee, Ju HyunKim, Hye-JungKim, Bong Tae
- [6] Structural insight into the binding mechanism of ATP to EGFR and L858R, and T790M and L858R/T790 mutants[J]. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2019, 37 (17): : 4671 - 4684Saldana-Rivera, LuciaBello, MartinianoMendez-Luna, David
- [7] Plasma MiRNA alterations between NSCLC patients harboring Del19 and L858R EGFR mutations[J]. ONCOTARGET, 2016, 7 (34) : 54965 - 54972Ma, YihanXu, PeiqiMi, YanjunWang, WenyiPan, XiaoyanWu, XiaotingHe, QiLiu, HongmingTang, WeiweiAn, Hanxiang
- [8] Different Efficacy of Osimertinib for EGFR Exon 19del or L858R in NSCLC Patients with Brain Metastases[J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E143 - E143Li, X.Li, B.Zhang, D.Zou, B.Wang, R. Z.Yu, J.Wang, L.
- [9] Highly sensitive detection of EGFR L858R mutation at the mRNA level[J]. ANALYTICAL BIOCHEMISTRY, 2022, 654Mai PhamQuynh PhamUng NguyenLanh NguyenHoa NguyenThang VuBa NguyenStenman, JakobHo Tho
- [10] An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy[J]. FRONTIERS IN IMMUNOLOGY, 2022, 13Lin, JingLiu, JunHao, Shi-guangLan, BinZheng, Xiao-binXiong, Jia-niZhang, Ying-qianGao, XuanChen, Chuan-benChen, LingHuang, Yu-fangLuo, HongYi, Yu-tingYi, XinLu, Jian-pingZheng, Xiong-weiChen, GangWang, Xue-fengChen, Yu